<DOC>
	<DOCNO>NCT01994993</DOCNO>
	<brief_summary>The main purpose study evaluate whether safe use various combination antibiotic ( ampicillin , metronidazole , clindamycin , piperacillin-tazobactam , gentamicin ) treat infant complicate intra-abdominal infection</brief_summary>
	<brief_title>Antibiotic Safety ( SCAMP )</brief_title>
	<detailed_description>The commonly use antibiotic infant complicate intra-abdominal infection label use population safety efficacy data lacking . This study provide safety information require labeling . In addition , pharmacokinetics ( PK ) effectiveness data also collect study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>1 . Informed consent obtain parent ( ) legal guardian ( ) ( Groups 15 ) 2 . ≤33 week gestation birth ( Groups 13 , 5 ) 3 . ≥34 week gestation birth ( Groups 4 5 ) 4 . PNA &lt; 121 day ( Groups 15 ) 5 . Sufficient venous access permit administration study drug ( intravenous [ IV ] ) ( Groups 15 ) 6 . Presenting physical , radiological , and/or bacteriological finding complicate intraabdominal infection within 48 hour prior randomization/first study drug dose ( Groups 14 ) ** . Complicated intraabdominal infection include secondary peritonitis , NEC grade II high Bell 's criterion , Hirschsprung 's disease perforation , spontaneous intestinal perforation , meconium ileus perforation , bowel obstruction perforation , gastroschisis necrosis and/or perforation , omphalocele necrosis and/or perforation , neonatal appendicitis , intestinal pneumatosis portal venous gas , free peritoneal air abdominal radiographic examination , abdominal abscess . 7 . Suspected confirmed infection study drug may provide therapeutic benefit plan CSF collection per standard care ( Group 5 ) . Exclusion Criteria* 1 . History anaphylaxis response study drug ( Groups 15 ) 2 . Serum creatinine &gt; 2 mg/dL within 48 hour measurement prior close randomization /first study drug dose ( Groups 1 5 ) ** 3 . Known ALT &gt; 250 U/L AST &gt; 500 U/L measurement closest time randomization first study drug dose ( Groups 15 ) ** 4 . Any condition , judgment investigator , precludes participation could affect participant safety ( Groups 15 ) Do apply Group 5 participant receive drug per standard care Criteria must satisfy randomization ( randomize Groups 13 ) first study drug dose ( nonrandomized Groups 13 , Group 4 Group 5 ) , whichever come first .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Days</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Antibiotics</keyword>
	<keyword>ampicillin</keyword>
	<keyword>metronidazole</keyword>
	<keyword>clindamycin</keyword>
	<keyword>piperacillin-tazobactam</keyword>
	<keyword>Safety</keyword>
	<keyword>Infants</keyword>
	<keyword>Intra abdominal infection</keyword>
</DOC>